THERAPY: The role of liquid biopsies to manage and predict PRRT for NETs
Patients with neuroendocrine tumours are increasingly treated with peptide receptor radionuclide therapy. However, tumour somatostatin receptor expression evaluation cannot accurately predict who will respond to therapy. Additional criteria to identify which patients are most likely to respond and those who will develop radiation-associated sequelae are critical requirements.
Refers to Strosberg, J. et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017)